Heestermans, Marco http://orcid.org/0000-0002-5788-6653
Naudin, Clément http://orcid.org/0000-0002-6777-9587
Mailer, Reiner K.
Konrath, Sandra
Klaetschke, Kristin
Jämsä, Anne
Frye, Maike http://orcid.org/0000-0002-6257-7636
Deppermann, Carsten
Pula, Giordano
Kuta, Piotr
Friese, Manuel A. http://orcid.org/0000-0001-6380-2420
Gelderblom, Mathias
Sickmann, Albert
Preston, Roger J. S.
Nofer, Jerzy-Roch
Rose-John, Stefan http://orcid.org/0000-0002-7519-3279
Butler, Lynn M.
Salomon, Ophira
Stavrou, Evi X. http://orcid.org/0000-0002-6075-7609
Renné, Thomas http://orcid.org/0000-0003-4594-5975
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (A11/SFB 877, B8/SFB 841, P6/KFO 306)
Article History
Received: 4 June 2020
Accepted: 31 August 2021
First Online: 22 September 2021
Competing interests
: Diagnostic use of soluble FXII activating agents that target the PR domain is patent protected by the University of Hamburg and T.R. (EU and U.S. reference numbers EP18736859.2 and US16/622064). All other authors declare no conflict of interest.